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1. Introduction 14 
Approximately 200 million prescriptions are issued annually for children and young people in the UK 15 
(Costello et al., 2004). It has been estimated that 5 - 10% of young people worldwide suffer from 16 
chronic health conditions (Newacheck et al., 2000).  17 
Children with chronic conditions may be prescribed a variety of medicines and have complex 18 
regimes. There is evidence to suggest that adherence with prescribed medication is lower amongst 19 
adolescents and children than in adults (Staples and Bravender, 2002). Medication adherence rates 20 
between 11% and 93% in paediatric patients have been reported (Winnick et al., 2005). 21 
Acceptability has previously been defined as the overall ability of a patient/ caregiver to use a 22 
medicinal product as intended / authorised (Kozarewicz, 2014). Acceptability of a medicinal product 23 
has potential to significantly affect the patient’s adherence and therefore is likely to influence safety 24 
and efficacy of a product (Kozarewicz, 2014). Usability has been used interchangeably with ‘human 25 
factors’ and defined as a ‘multi-dimensional quality’, which reflects human ability ‘to interact easily 26 
and relatively error-free with a system or product.’ This may be translated in medical device terms, 27 
as the measure of how well a device works to meet user expectation, thus administration without 28 
frustration (BSI, 2015). 29 
 30 
Over the past two decades, trends in post-market adverse events related to design issues affecting 31 
usability of medical devices have been reported. These use-related design issues have resulted in 32 
problems with therapies (BSI, 2015).  33 
 34 
There is a paucity of research exploring barriers to non-oral formulations and devices used in the 35 
administration of formulations to paediatric patients within a pragmatic environment. However, 36 
barriers to medicines administration undoubtedly influence medicines adherence. Studies 37 
conducted with healthcare professionals have identified various issues with the usability and child 38 
acceptance of non-oral formulations and devices in children, (Venables et al., 2012; Walsh et al., 39 
2015). In order to improve formulations for children in the future, it is inevitable that one needs to 40 
understand barriers to administration, thus usability can inform future drug development work to 41 
improve design of medicinal products and medical devices. Children have different sensory 42 
perceptions to adults and are therefore the most important participants for acceptability studies in 43 
paediatric patients; thus it was necessary to identify barriers to administration from their 44 
perspective to inform the design of future formulations and administration devices. 45 
 46 
More information is needed to understand the factors that influence child and carers and their 47 
attitudes to medicines adherence to inform future paediatric formulation design. Regulatory 48 
agencies have also noted the importance of acceptability of devices for the administration of non-49 
oral formulations including EMA (2014) guidelines and guidance from BSI on ‘user interface 50 
design/evaluation’ supports FDA (2011) draft guidance on optimizing medical device design, which 51 
outlines potential human factors and usability engineering (HFE/UE) analyses that should be 52 
conducted for medical devices, which includes formative evaluations of medical devices.  53 
 54 
The aims of the present study were: (i) to establish the prevalence and nature of barriers to 55 
administering non-oral formulations to paediatric patients with chronic conditions (ii) to determine 56 
how frequently any factors identified with non-oral formulations (including devices used to 57 
administer formulations) are involved in compromising acceptability and refusal and (iii) to inform 58 
future paediatric (non-oral) medicines formulation and device design, the pharmaceutical industry 59 
and prescribers. 60 
1. Materials and Methods 61 
1.1 Data collection tool 62 
A semi-structured interview was selected for this study to obtain the qualitative data required and 63 
provide an appropriate balance in data collection and subsequent analysis (Malim and Birch, 1996). 64 
A multidisciplinary research team (Professor in Clinical Pharmacy, paediatric consultant and 65 
pharmacist) generated an outline of barriers to administering non-oral formulations to children; 66 
medicines administration issues were refined via four focus groups with healthcare professionals at 67 
the University Hospital Coventry and Warwickshire (UHCW) and Birmingham Children’s Hospital 68 
(BCH). The data collected, in addition to self-report methodologies referenced in published studies 69 
(Medical Adherence Measure – MAM (Ingerski et al., 2009; Zelikovsky et al., 2008), Treatment 70 
Interview Protocol – TIP (Marhefka et al., 2004), Paediatric AIDS Clinical Trials Group PACTG 71 
questionnaire (NIAID) and Morisky Scales (Morisky et al., 2008,1986) were used to inform the design 72 
of the self-report semi-structured interview tool. The Young Persons Advisory Group (YPAG) at 73 
Birmingham Children’s Hospital (n = 12 members) reviewed the tool to ensure that it was age 74 
appropriate. The 13-item self-report tool used in the semi-structured interviews was designed to 75 
collect data exploring medicines acceptability and adherence. Open questions were used to elicit 76 
barriers to medicines administration and a closed question was used to identify rates of refusal. The 77 
tool used has been previously reported by Venables et al. (2015). 78 
A semi-structured interview was conducted by a single researcher not previously known to the 79 
patients) to minimise variation in approach and the responses were entered manually onto a 80 
structured data record during each interview. The interviews (maximum duration of 45 min) were 81 
conducted in a private area at the paediatric outpatients department at UHCW at times scheduled to 82 
coincide with routine clinical appointments. 83 
Ethical approval was granted by the South Birmingham REC and informed consent was obtained 84 
from all participants. 85 
1.2 Qualitative analysis 86 
Thematic analysis was conducted using a frame-work approach to form a coding spine. Thematic 87 
content analysis (Pope et al., 2000) was used to identify and group common themes arising from the 88 
qualitative data, relating to administering non-oral formulations.  89 
1.3 Study setting and participants 90 
A pragmatic approach was employed to identify and recruit participants resulting in a total of 1559 91 
study invitation letters being posted to patients (via their parent/carer) due to attend follow-up 92 
paediatric clinics (1448/1559) or handed out on the paediatric wards (111/1559) at UHCW. Study 93 
interviews were conducted with parents or carers (if legal guardians) of children or young people, or 94 
with young people directly. The opportunity to assent and participate alone was given to 12–16 95 
years old providing parent or carer consent was also obtained. Young people aged 16 – <18 years of 96 
age were permitted to consent alone and encouraged to discuss the study with a parent or legal 97 
guardian before providing consent. It was necessary to include young people (those over 12 years of 98 
age), where appropriate as this sub-population reported increased empowerment over medicines 99 
administration. Parents’ and carers’ views were more useful for younger children where they did not 100 
have the cognitive capability to participate alone or were not responsible for medicines 101 
administration. 102 
Age-appropriate study information was provided to potential participants at least 24 h before asking 103 
for participation in the study. A total of 191 general and speciality outpatient clinics were targeted 104 
covering a wide range of chronic conditions (e.g. epilepsy, cystic fibrosis, neoplasms, cardiac 105 
disorders, endocrine disorders, tuberculosis, HIV, renal diseases, rheumatological diseases and 106 
survivors of neonatal intensive care). It should be noted that not all patients in clinics were 107 
prescribed medications; therefore not all patients were eligible for study inclusion. There was a 108 
scheduled approach to accessing patients at these clinics on a rotating basis to ensure wide coverage 109 
of the target patient population. UHCW is a teaching hospital with three age-banded paediatric 110 
wards. Inpatients from all three paediatric wards at UHCW were included at the recruitment phase 111 
to minimise the risk of missing eligible patients who were hospitalised during the study period.  112 
1.4 Inclusion criteria 113 
Children (aged 0–<18 years) with chronic conditions and their parents/ carers were recruited to the 114 
study. Patients were eligible for inclusion if they had been taking a prescribed medication for a 115 
chronic condition for at least one month prior to their outpatient appointment. 116 
2 Results 117 
A total of 280 participants consented to the FIND OUT study (Venables et al., 2015). In total, 90 118 
participants were prescribed at least one non-oral formulation. Interviews exploring barriers to 119 
administering non-oral formulations were completed with 61 parents/guardians and 29 young 120 
people (in the presence of a parent/carer (n = 24), in the absence of a parent/carer (n = 5)). 121 
The children prescribed only oral formulations will not be discussed in this paper; these have been 122 
published previously (Venables et al., 2015). 123 
2.1 Participant demographics and non-oral formulations 124 
The 90 children receiving non- oral formulations were categorised into three age groups: 0–4 years 125 
(n = 25), 5–11 years (n = 36) and 12– <18 years (n = 29), age bandings were based on pre-school; 126 
school-age and adolescents to match cognitive function. See Table 1 for the frequency of non-oral 127 
formulation types prescribed. In total, 148 non-oral formulations were prescribed across the cohort. 128 
 129 
 130 
 131 
 132 
Table 1. Primary diagnoses and number of patients diagnosed 133 
Main diagnosis Number of study patients with this primary 
diagnosis 
Gastro-intestinal 12 
Neoplasm 2 
Epilepsy  4 
Allergies 2 
CF 8 
Arthritis / uveitis  14 
Growth disorders 10 
Thyroid condition 5 
Blood-related disorder 2 
Asthma 15 
Renal disease 5 
Cardiac disease 2 
DM type 1 6 
Chronic fatigue syndrome 2 
Scleroderma 1 
 134 
2.2 Medicines refusal 135 
In total, data about the refusal of formulations was gained for 70% (103/148) non-oral formulations. 136 
Of these, 7% (7/103) of non-oral formulations were reported to have been completely refused 137 
2.3 Barriers to non-oral medicines administration 138 
In total, 88 barriers to medicines administration were reported across the 148 non-oral 139 
formulations.  A barrier to administration in this study is defined as a factor which has potential to 140 
affect administration; this includes poor child acceptance and interference with daily living (more 141 
examples of reports are reported in the following results sections). See Figure 1 below for the 142 
frequency of reported barriers to administration across different non-oral formulations. 143 
 144 
 145 
Figure 1. The frequency of reported barriers to administration across different non-oral 146 
formulations. 147 
Over 60% of participants reported at least one barrier to non-oral medicines administration; the 148 
impact of age on reported barriers is shown in Figure 2 below.  149 
Figure 2. The frequency of children/ parents reporting at least one barrier to administering non-oral 150 
formulations.  151 
In addition to barriers to administration, for almost one quarter of non-oral formulations, problems 152 
with obtaining formulations were highlighted.   153 
2.3.1 Inhaled formulations 154 
49 children (0-4 years n=17, 5-11 years n=21, 12-<18 years n=11) were prescribed inhaled 155 
formulations.  In total, 55% (27/49) of children prescribed inhaled medication reported a barrier to 156 
administration (0-4 years n=12, 5-11 years n=9, 12-<18 years n=6). See Fig.1 for the number of 157 
reported barriers to inhaled medication. See table 2 for themes arising from the data on inhaled 158 
formulations and associated reporting frequency. 159 
Table 2. Themed barriers to administration of inhaled formulations reported by parents/carers and 160 
young people 161 
Barrier theme Number of reports 
Difficulty with face mask/spacer devices doesn’t 18 
like face mask/spacer.  Spacer too big 
inconvenient to transport/ difficulty washing.   
 
Difficulty with /inconvenience of preparation - 
Time consuming /preparation effort/puts off 
eating/interferes with daily living as have to be 
at home.  
12 
Measuring and delivering accurate dose - 
Device – unsure how much drug is 
delivered/hard to gauge how much is actually 
released relies on breath/ sometimes dose not 
released 
6 
Formulation options - doesn’t like nebuliser 
prefer tablet, formulation difficult, not ideal 
5 
 
Age-appropriateness/appeal - Not child friendly 
or attractive to children 
2 
Palatability issues (texture/consistency/taste) - 
too powdery, bad taste when hits back of throat  
3 
 
Storage – nebuliser solution has to be kept in 
freezer storage bag when travelling 
1 
In addition, a positive comment was highlighted by a participant stating that inhalers with counters 162 
are valuable as they show how many doses are remaining. 163 
2.3.2 Parenteral formulations 164 
In total, data was explored for 43 parenteral formulations (including IM, IV and SC formulations) 165 
prescribed to 36 children (0-4 years n=6, 5-11 years n=15, 12-<18 years n=15).  Three quarters - 75% 166 
(27/36) of children prescribed parenteral formulations reported a barrier to administration (0-4 167 
years n=2, 5-11 years n=13, 12-<18 years n=12). See Fig.1 for the number of reported barriers to 168 
parenteral formulations. See table 3 for themes arising from the data on parenteral formulations 169 
and associated reporting frequency. 170 
Table 3. Themed barriers to administration of parenteral formulations reported by parents/carers 171 
and young people 172 
Barrier theme Number of reports 
Dislikes formulation/ prefer alternative 
formulation as dislikes injection, another 
formulation preferred, (e.g. tablets 
banana/strawberry liquid),does not like route of 
administration 
13 
Fear of pain / effects at site of administration - 
bruising, needle phobia (change to pen device 
like ‘etanercept’ so cannot see needle, prefer 
10 
 
diabetic pen), bleeding at site, stinging at site, 
preparation time increases anxiety. 
Difficulty with device (human error factors) - 
Device stiffness, difficult to administer, parents 
have to administer as too difficult for child yet 
child wants to be more independent, 
incompatibility with certain needles and the 
device, insulin pump does not test blood sugar 
still need to finger-prick. 
6  
 
Frequency of dosing - issue with twice daily 
dosing of injection 
1  
 
Difficulty with preparation of dose 1 
Volume 1 
Short expiry dates 1 
Storage  - fridge 1 
 173 
2.3.3 Dermal/transdermal 174 
In total, data was explored for 7 dermal/transdermal formulations prescribed to 5 children (0-4 years 175 
n=1, 5-11 years n=1, 12-<18 years n=3). 176 
5 barriers to medicines administration were reported across these formulations for 3 children (5-11 177 
years n=1, 12-<18 years n=2). See table 4 for themes arising from the data on dermal/transdermal 178 
formulations and associated reporting frequency. 179 
Table 4. Themed barriers to administration of dermal and transdermal formulations reported by 180 
parents/carers and young people 181 
Barrier theme Number of reports 
Texture/ consistency - creams: greasy difficult 
for school, child avoids applying this. Ointments:  
very greasy difficult for school, child avoids 
applying this. 
4 
Measuring and delivering accurate dose - 
Transdermal patch – child is drowsy if cut in half 
inaccurately, other comment – mom was 
concerned as to whether she has cut the patch 
accurately for homogenous drug release; there is 
no score line, she reported using eye 
measurement 
1 
2.3.4 Ocular 182 
In total, data was explored for 4 ocular formulations prescribed to 3 children (0-4 years n=1, 12-<18 183 
years n=2). A single barrier to medicines administration was reported across these formulations; 184 
difficulty with device – chloramphenicol eye ointment was described by a mother as very difficult to 185 
administer to a child owing to the child not wanting to sit still and not liking eyes to be touched (0-4 186 
years n=1).  187 
2.3.5 Nasal 188 
In total, data was explored for 3 nasal formulations prescribed to 3 children (0-4 years n=1, 5-11 189 
years n=1, 12-<18 years n=1). A single barrier to medicines administration was reported across these 190 
formulations; Issue with the volume of a nasal spray – ‘2 sprays for one dose is a large volume,  child 191 
does not like this large volume’ (5-11 years n=1). 192 
2.3.6 Contraceptive implant device 193 
No issue was reported for the contraceptive implant device prescribed (1 child prescribed a 194 
contraceptive implant device, 12-<18 years n=1). 195 
2.3.7 Rectal 196 
No issues were reported for the two enema formulations prescribed (2 children prescribed rectal 197 
formulations, 0-4 years n=1, 12-<18 years n=1). 198 
3 Discussion 199 
In total, 7% of doses were actually refused, however, a plethora of barriers (88 reported barriers 200 
across 148 non-oral formulations) to administration were reported. It was necessary to identify 201 
these barriers in order to improve usability, i.e. reduce frustration, resistance and potentially time 202 
delay of administration. Further to these barriers, reports of issues with obtaining medicines were 203 
reported. 204 
64% (58/90) of participants reported at least one barrier to non-oral medicines administration (0-4 205 
years n=15, 5-11 years n=24, 12-<18 years n=19). The highest rate of barriers (67% of children 206 
prescribed non-oral formulations) was reported by parents of children in the 5-11 years age band, 207 
although similar frequency of reports were recorded for children aged 0-4 years and 12-<18 years 208 
(60% and 66% respectively). 209 
For inhaled formulations and associated devices, key issues identified in order of highest reporting 210 
frequency (n=≥10 reports) were: Difficulty with face masks/ spacer devices and difficulty with/ 211 
inconvenience of preparation. Further barriers: measuring and delivering an accurate dose, difficulty 212 
with other devices, age-appropriateness/appeal, texture/consistency, taste and storage were 213 
reported in smaller frequencies.  214 
Findings of this study demonstrate that barriers to administration of inhaled formulations were 215 
reported more by children within the youngest age band (0-4 years). This may be related to high 216 
frequency of prescribing of spacer devices (with a face mask where necessary) in children under the 217 
age of 5 with chronic asthma, in-line with current NICE guidance (NICE, 2000). It is crucial that 218 
findings inform formulation design and development, thus the pharmaceutical industry should 219 
consider methods to improve patient acceptance and usability. It may be possible to improve child 220 
acceptance if spacer devices were designed to appeal to children and be suitable in terms of age 221 
appropriateness; it may be beneficial to use child-friendly designs in future design stages of both 222 
products and patient information leaflets provided with these. Complementing some of these 223 
findings, a study by Walsh et al. (2015) investigating healthcare professionals’ perspectives identified 224 
similar problems with respiratory devices including: too complicated to use, unpleasant taste, 225 
coordination difficulties and lack of patient tolerance (especially to spacer/facemask). Similarly they 226 
reported the use of child-friendly designs to improve child acceptance (Walsh et al., 2015). 227 
With regard to parenteral formulations, key issues in order of highest reporting frequency (n=≥10 228 
reports) were: disliking formulation/ preferring an alternative and fear of pain /effects at site of 229 
administration. Other barriers reported in smaller frequencies were: difficulty with device, frequency 230 
of dosing, difficulty with preparation of dose, volume, short expiry dates and storage.  231 
Results show a higher frequency of reporting of barriers to parenteral administration amongst the 5-232 
11 and 12-<18 years age band compared to children aged 0-4 years. This may be associated with 233 
children at the middle and upper end of the paediatric spectrum desiring more empowerment over 234 
their medication, thus being involved with the administration process. As a child matures in to 235 
adolescence, generally reduced parental guidance and supervision is observed. Often, parents 236 
become less responsible for administering medication and also reminding their child to administer 237 
medication as the child gets older (WHO, 2003). One factor which may affect adherence is the 238 
interference of the treatment with needs and lifestyles of the young person (Michaud et al., 2004). 239 
The majority of young people strive to lead a stereotypical ‘teenage life’ and are likely to undergo 240 
peer pressure, and feel the stigma associated with administering medication (e.g. when attending 241 
social events) (Michaud et al., 2004). This should be taken into account when designing parenteral 242 
devices for the paediatric spectrum. Parenteral formulations are often prescribed for conditions 243 
such as juvenile diabetes, haemophilia and rheumatoid arthritis; research exploring young people 244 
with these conditions has revealed the potential vulnerability of young people to medication non-245 
adherence (WHO, 2003). This correlates with the findings of the current study, which highlights the 246 
prevalence of barriers to parenteral administration across a paediatric population. 247 
There is a steady increase in both pinch strength and grasp which correlates to increase in 248 
chronological age (Ager et al., 1984; Häger‐Ross et al., 2002) and development (Ager et al., 1984). It 249 
has been previously reported that the peak grip strength of a 9 year old is comparable to that of a 250 
healthy man/woman (Nordenskio¨ld & Grimby 2003), thus this should be considered when designing 251 
devices that are ‘usable’ for children of different ages and abilities. Furthermore, it is vital that the 252 
pharmaceutical industry recognise and inform device design with respect to dexterity issues which 253 
may be experienced by certain paediatric patient groups whom often require devices, e.g. children 254 
with juvenile idiopathic arthritis.  The ethos is that parents/young people should be able to use 255 
medical devices safely and effectively, without unintentionally making errors that could compromise 256 
positive outcomes. 257 
Reports of palatability issues for three inhaled formulations included the ‘powdery’ texture and ‘bad 258 
taste when hits back of throat’; such findings should be explored further and used to direct future 259 
formulation design. ‘Greasy’ consistency was reported as a barrier to administration for a child 260 
prescribed ointments and creams. This has been similarly reported in other studies.  Santer et al. 261 
(2013) described carers’ reports which included “waxy and slippery and very sticky”. Similarly a 262 
further study reports the unappealing formulation, such as smell or greasiness of my child’s topical 263 
treatments, making it difficult to treat the disease (Ellis et al., 2011). Methods used to overcome 264 
child resistance to topical application have been reported to include bribes, games and distraction 265 
therapy during application (e.g. Television) (Santer et al., 2013). Such methods, alongside parental/ 266 
young person educational techniques may help to overcome barriers to administration and should 267 
be explored further in future studies.  268 
The current study findings identify barriers to administering non-oral formulations and provide 269 
insight into improving the design of future devices. Such findings should be used alongside existing 270 
guidance on acceptability of formulations (EMA, 2014), draft guidance on usability (FDA, 2011) and 271 
BSI guidance on ‘user interface design/evaluation’ to inform the pharmaceutical industry and 272 
optimise medical device design. 273 
Both the FDA and IEC 62366 stress the importance of a UI design process that is driven by iterative 274 
formative evaluations conducted early-on and throughout the design process of a device; this is 275 
crucial in view of minimising risk thus human error and also improving usability of devices (BSI, 276 
2015).  If usability is not optimal, medicines administration may be slower and more prone to error; 277 
this could affect medicines adherence and patient/parent safety. Furthermore, if a product has 278 
improved usability, this may result in a competitive advantage from a marketing perspective.  279 
It is imperative that children and young people are involved in the design or medical devices as well 280 
as in the writing of appropriate instructions for use to optimise this process, in order to inform 281 
future formulation development at an age-appropriate level.  This should promote the production of 282 
devices that are suitable across the paediatric spectrum. In addition, the role of educating and 283 
communicating with parents and young people effectively to optimise adherence to medication 284 
regimens should be explored further. Current research evidence highlights the importance of 285 
effective communication to support paediatric adherence (DiMatteo, 2004). 286 
Further studies should be conducted to explore barriers to usability and patient acceptance of non-287 
oral formulations and device on a larger scale, noting specific brands to inform pharmaceutical 288 
industry. 289 
4 Conclusions 290 
This pragmatic and novel study provides insight on the acceptance of non-oral formulations across a 291 
paediatric population suffering from various chronic conditions. This study complements the work 292 
conducted by: the EUPFI on acceptability (Kozarewicz, 2014); Walsh et al. (2015) on healthcare 293 
professionals’ perceptions of devices and Venables et al. (2015) exploring barriers to oral medicines 294 
administration. This work complements BSI guidance on human factors and usability engineering 295 
(BSI, 2015) and that drafted by FDA (2011) on the need for evaluations of medical devices from users 296 
to determine usability. As children must not be considered mini-adults it is vital to ensure that data 297 
used to inform future pharmaceutical development of non-oral formulations and devices is from the 298 
representative patient group.  299 
The findings of the current study should be used to inform future development of non-oral 300 
formulations and medical devices, suitable in terms of safety, efficacy usability and acceptability to 301 
paediatric patients and their parents/carers. 302 
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